The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Pamela B. Teaster, PhD, MA, MS and Al O. Giwa, LLB, MD, MBA, MBE
Since ageism contributes to global mental health inequity among older people, responding to their needs should be a clinical, ethical, and policy priority.
AMA J Ethics. 2023;25(10):E765-770. doi:
10.1001/amajethics.2023.765.
Dr Chad M. Teven joins Ethics Talk to unravel some current and a few hoped-for surgical applications of AI and to model for us how we should be critically engaging with AI surgical research and scholarship.
Lydia Smeltz, Susan M. Havercamp, PhD, and Lisa Meeks, PhD, MA
Lack of disability-competent health care contributes to inequitable health outcomes for persons with disabilities, the largest minoritized population in the world.
AMA J Ethics. 2024;26(1):E54-61. doi:
10.1001/amajethics.2024.54.
Dr Lisa Fuller joins Ethics Talk to discuss her article: “How Should Organizations and Clinicians Help Marginalized Patients Manage Loneliness as a Harm of Climate Change?”
Dr David Marcus joins Ethics Talk to discuss his article: “When, If Ever, Is It Appropriate to Regard a Patient as ‘Too Medically Complex’ for One Inpatient Service, But Not Another?”